Bionomics Ltd. (BNOEF) 0.3900 $BNOEF
Malignant Pleural Mesothelioma Pipeline Review, H1 2015 - 29 Companies & 36 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfkk97/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Oxford BioMedica plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - amatuximab - anetumab ravtansine - ascrinvacumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - CRS-207 - defactinib hydrochloride - FP-1039 - ganetespib - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - pegargiminase - pembrolizumab - porfimer sodium - RG-7787 - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - TargomiRs - trabectedin - tremelimumab - TroVax - Vaccine For Oncolytic Newcastle Disease Virus For more information visit http://www.researchandmarkets.com/research/kf...nt_pleural
ADRO: 30.58 (+0.28), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VSTM: 7.36 (+0.24), SNTA: 2.16 (-0.01), MRK: 57.95 (+0.57), JUNO: 52.05 (+1.72), CXRX: 73.69 (+1.67), FPRX: 26.01 (+0.37), NVS: 103.22 (+3.20)
Bionomics Files Patent For Use Of BNC105 In Combination With PD-1 And CTLA-4 Immuno-Oncology Antibodies
PR Newswire - Mon Jun 15, 5:00AM CDT
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, announced today that it filed a patent application covering the use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer. This new patent is based on important preclinical findings regarding the synergistic effects in preclinical models of a combination of the company's proprietary novel oncology compound BNC105 and antibodies against known immuno-oncology targets.
BNO: 20.81 (+0.03)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), OMER: 17.33 (+0.29), JNJ: 99.53 (+1.13), NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), MRNS: 13.62 (+1.72), ABBV: 69.23 (+1.26), ITCI: 34.76 (+1.70), CUR: 1.69 (-0.01), NVS: 103.22 (+3.20)
Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
PR Newswire - Mon Apr 20, 5:00AM CDT
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) , a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.
BNO: 20.81 (+0.03)
Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting
PR Newswire - Fri Apr 17, 5:00AM CDT
Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the presentation of data from three of its most advanced oncology programs at the upcoming American Association for Cancer Research (AACR) 106th Annual Meeting being held from April 18-22, 2015 in Philadelphia, PA USA.
BNO: 20.81 (+0.03)
BNC105 Biomarker Data to Be Presented at Asian Oncology Conference
PR Newswire - Fri Apr 10, 5:00AM CDT
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.
BNO: 20.81 (+0.03)
Chronic Pain Therapeutics Pipeline Review 2015 - 62 Companies & 138 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98dtzm/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Akron Molecules AG - Allergan, Inc. - arGEN-X BV - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - BCN Peptides, S.A. - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DURECT Corporation - Egalet Corporation - Eli Lilly and Company - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/98...ronic_pain
BDSI: 8.64 (+0.15), ENDP: 83.12 (+2.66), LLY: 88.29 (+0.81), DRRX: 2.48 (+0.15), AGN: 312.13 (+8.03), JNJ: 99.53 (+1.13), ACAD: 43.94 (+1.76), EGLT: 12.42 (+0.36), AZN: 66.45 (+1.90), ABBV: 69.23 (+1.26), PTIE: 1.70 (unch)
Bionomics Begins Trading on OTCQX Marketplace
PR Newswire - Mon Mar 02, 7:00AM CST
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced its ordinary shares commenced trading on the OTCQX marketplace in the U.S., effective March 2, 2015.
OTC Markets Group Welcomes Bionomics to OTCQX®
PR Newswire - Mon Mar 02, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Bionomics Ltd. (ASX: BNO; OTCQX: BNOEF), a global biopharmaceutical company developing better treatments for cancer and central nervous system disorders, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
Malignant Pleural Mesothelioma Pipeline Review, H1 2015 - 29 Companies & 36 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfkk97/malignant_pleural) has announced the addition of the "Malignant Pleural Mesothelioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Advantagene, Inc. - Amphera BV - Bayer AG - Biogen, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CanBas Co., Ltd. - Concordia Healthcare Corp. - EnGeneIC Ltd - F. Hoffmann-La Roche Ltd. - Five Prime Therapeutics, Inc. - Genelux Corporation - GlaxoSmithKline plc - Juno Therapeutics Inc. - MedImmune, LLC - Merck & Co., Inc. - MolMed S.p.A. - Morphotek, Inc. - Novartis AG - Oxford BioMedica plc - Pfizer Inc. - Pharma Mar, S.A. - Polaris Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Verastem, Inc. - Virttu Biologics Limited Drug Profiles - amatuximab - anetumab ravtansine - ascrinvacumab - BG-00001 - BMS-986148 - BNC-105 - CBP-501 - Cell Therapy 1 for Oncology - CRS-207 - defactinib hydrochloride - FP-1039 - ganetespib - Gene Therapy for Malignant Pleural Mesothelioma - Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - GLONC-1 - GSK-2256098 - HSV-1716 - iCasp9M28z - JTCR-016 - MesoCancerVac - MesoCART - Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - napabucasin - NGR-hTNF - nintedanib - pegargiminase - pembrolizumab - porfimer sodium - RG-7787 - Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - TargomiRs - trabectedin - tremelimumab - TroVax - Vaccine For Oncolytic Newcastle Disease Virus For more information visit http://www.researchandmarkets.com/research/kf...nt_pleural
ADRO: 30.58 (+0.28), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VSTM: 7.36 (+0.24), SNTA: 2.16 (-0.01), MRK: 57.95 (+0.57), JUNO: 52.05 (+1.72), CXRX: 73.69 (+1.67), FPRX: 26.01 (+0.37), NVS: 103.22 (+3.20)
Bionomics Files Patent For Use Of BNC105 In Combination With PD-1 And CTLA-4 Immuno-Oncology Antibodies
PR Newswire - Mon Jun 15, 5:00AM CDT
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, announced today that it filed a patent application covering the use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer. This new patent is based on important preclinical findings regarding the synergistic effects in preclinical models of a combination of the company's proprietary novel oncology compound BNC105 and antibodies against known immuno-oncology targets.
BNO: 20.81 (+0.03)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), OMER: 17.33 (+0.29), JNJ: 99.53 (+1.13), NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), MRNS: 13.62 (+1.72), ABBV: 69.23 (+1.26), ITCI: 34.76 (+1.70), CUR: 1.69 (-0.01), NVS: 103.22 (+3.20)
Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
PR Newswire - Mon Apr 20, 5:00AM CDT
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) , a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.
BNO: 20.81 (+0.03)
Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting
PR Newswire - Fri Apr 17, 5:00AM CDT
Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the presentation of data from three of its most advanced oncology programs at the upcoming American Association for Cancer Research (AACR) 106th Annual Meeting being held from April 18-22, 2015 in Philadelphia, PA USA.
BNO: 20.81 (+0.03)
BNC105 Biomarker Data to Be Presented at Asian Oncology Conference
PR Newswire - Fri Apr 10, 5:00AM CDT
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.
BNO: 20.81 (+0.03)
Chronic Pain Therapeutics Pipeline Review 2015 - 62 Companies & 138 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98dtzm/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Akron Molecules AG - Allergan, Inc. - arGEN-X BV - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - BCN Peptides, S.A. - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DURECT Corporation - Egalet Corporation - Eli Lilly and Company - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/98...ronic_pain
BDSI: 8.64 (+0.15), ENDP: 83.12 (+2.66), LLY: 88.29 (+0.81), DRRX: 2.48 (+0.15), AGN: 312.13 (+8.03), JNJ: 99.53 (+1.13), ACAD: 43.94 (+1.76), EGLT: 12.42 (+0.36), AZN: 66.45 (+1.90), ABBV: 69.23 (+1.26), PTIE: 1.70 (unch)
Bionomics Begins Trading on OTCQX Marketplace
PR Newswire - Mon Mar 02, 7:00AM CST
Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced its ordinary shares commenced trading on the OTCQX marketplace in the U.S., effective March 2, 2015.
OTC Markets Group Welcomes Bionomics to OTCQX®
PR Newswire - Mon Mar 02, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Bionomics Ltd. (ASX: BNO; OTCQX: BNOEF), a global biopharmaceutical company developing better treatments for cancer and central nervous system disorders, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
